Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08OUU
|
||||
Former ID |
DIB013260
|
||||
Drug Name |
Genevx
|
||||
Synonyms |
Ad5-VEGF145; Restenosis therapy, Collateral; VEGF gene therapy, Collateral
|
||||
Indication | Angina pectoris [ICD9: 413; ICD10:I20] | Terminated | [1] | ||
Company |
Collateral Therapeutics Inc
|
||||
Target and Pathway | |||||
Target(s) | VEGF receptor | Target Info | Modulator | [2] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013170) | ||||
REF 2 | Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury. Circulation. 2005; 112: 2477-2486. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.